These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa. Pilmis B; Petitjean G; Lesprit P; Lafaurie M; El Helali N; Le Monnier A; Eur J Clin Microbiol Infect Dis; 2019 Aug; 38(8):1457-1461. PubMed ID: 31073653 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring and Prolonged Infusions of Ceftolozane/Tazobactam for MDR/XDR Pseudomonas aeruginosa Infections: An Observational Study. Navarrete-Rouco ME; Luque S; Sorlí L; Benítez-Cano A; Roberts JA; Grau S Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):561-566. PubMed ID: 35657580 [TBL] [Abstract][Full Text] [Related]
4. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909 [TBL] [Abstract][Full Text] [Related]
5. Impact of Ceftolozane-Tazobactam vs. Best Alternative Therapy on Clinical Outcomes in Patients with Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Lower Respiratory Tract Infections. Holger DJ; Rebold NS; Alosaimy S; Morrisette T; Lagnf A; Belza AC; Coyne AJK; El Ghali A; Veve MP; Rybak MJ Infect Dis Ther; 2022 Oct; 11(5):1965-1980. PubMed ID: 36048335 [TBL] [Abstract][Full Text] [Related]
6. Ceftolozane/tazobactam for the treatment of XDR Pseudomonas aeruginosa infections. Escolà-Vergé L; Pigrau C; Los-Arcos I; Arévalo Á; Viñado B; Campany D; Larrosa N; Nuvials X; Ferrer R; Len O; Almirante B Infection; 2018 Aug; 46(4):461-468. PubMed ID: 29594953 [TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing urinary tract and intraabdominal infections in Europe: report from an antimicrobial surveillance programme (2012-15). Pfaller MA; Bassetti M; Duncan LR; Castanheira M J Antimicrob Chemother; 2017 May; 72(5):1386-1395. PubMed ID: 28165526 [TBL] [Abstract][Full Text] [Related]
8. Ceftolozane-Tazobactam in the Treatment of Experimental Pseudomonas aeruginosa Pneumonia in Persistently Neutropenic Rabbits: Impact on Strains with Genetically Defined Mechanisms of Resistance. Petraitis V; Petraitiene R; Naing E; Aung T; Thi WP; Kavaliauskas P; Win Maung BB; Michel AO; Ricart Arbona RJ; DeRyke AC; Culshaw DL; Nicolau DP; Satlin MJ; Walsh TJ Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31235620 [TBL] [Abstract][Full Text] [Related]
9. Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients. Balandin B; Ballesteros D; Ruiz de Luna R; López-Vergara L; Pintado V; Sancho-González M; Soriano-Cuesta C; Pérez-Pedrero MJ; Asensio-Martín MJ; Fernández-Simón I; Rodríguez-Serrano D; Silva A; Chicot M; Iranzo R; Martínez-Sagasti F; Royuela A Int J Antimicrob Agents; 2021 Mar; 57(3):106270. PubMed ID: 33347991 [TBL] [Abstract][Full Text] [Related]
10. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497 [TBL] [Abstract][Full Text] [Related]
11. Clinical experience with ceftolozane/tazobactam in patients with serious infections due to resistant Pseudomonas aeruginosa. Xipell M; Paredes S; Fresco L; Bodro M; Marco F; Martínez JA; Soriano A J Glob Antimicrob Resist; 2018 Jun; 13():165-170. PubMed ID: 29366723 [TBL] [Abstract][Full Text] [Related]
12. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Farrell DJ; Sader HS; Flamm RK; Jones RN Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078 [TBL] [Abstract][Full Text] [Related]
13. A Multicenter Evaluation of Ceftolozane/Tazobactam Treatment Outcomes in Immunocompromised Patients With Multidrug-Resistant Hart DE; Gallagher JC; Puzniak LA; Hirsch EB; Open Forum Infect Dis; 2021 Mar; 8(3):ofab089. PubMed ID: 33796600 [TBL] [Abstract][Full Text] [Related]
14. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP. Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040 [TBL] [Abstract][Full Text] [Related]
15. Short-Term Effects of Appropriate Empirical Antimicrobial Treatment with Ceftolozane/Tazobactam in a Swine Model of Nosocomial Pneumonia. Motos A; Li Bassi G; Pagliara F; Fernandez-Barat L; Yang H; Aguilera Xiol E; Senussi T; Idone FA; Travierso C; Chiurazzi C; Amaro R; Yang M; Bobi J; Rigol M; Nicolau DP; Frigola G; Cabrera R; Ramirez J; Pelosi P; Blasi F; Antonelli M; Artigas A; Vila J; Kollef M; Torres A Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168605 [TBL] [Abstract][Full Text] [Related]
16. Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L. Natesan S; Pai MP; Lodise TP J Antimicrob Chemother; 2017 Oct; 72(10):2813-2816. PubMed ID: 29091209 [TBL] [Abstract][Full Text] [Related]
17. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease. Xiao AJ; Caro L; Popejoy MW; Huntington JA; Kullar R Infect Dis Ther; 2017 Mar; 6(1):137-148. PubMed ID: 28013453 [TBL] [Abstract][Full Text] [Related]